UBS Group Issues Pessimistic Forecast for Envista (NYSE:NVST) Stock Price

Envista (NYSE:NVST) had its price target dropped by analysts at UBS Group from $23.00 to $21.00 in a research note issued on Monday,Benzinga reports. The firm currently has a “neutral” rating on the stock. UBS Group’s target price points to a potential upside of 19.13% from the company’s current price.

Several other equities analysts also recently weighed in on the company. JPMorgan Chase & Co. dropped their price objective on Envista from $20.00 to $19.00 and set a “neutral” rating for the company in a research note on Thursday. Mizuho assumed coverage on shares of Envista in a research note on Wednesday, December 4th. They issued an “underperform” rating and a $20.00 price objective on the stock. Jefferies Financial Group increased their price target on shares of Envista from $20.00 to $22.00 and gave the company a “hold” rating in a research report on Thursday, January 23rd. Piper Sandler raised their price target on Envista from $17.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, February 3rd. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Envista in a research note on Thursday. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and three have issued a buy rating to the stock. According to MarketBeat, Envista has an average rating of “Hold” and a consensus price target of $20.32.

Envista Trading Down 4.4 %

Shares of NYSE NVST traded down $0.80 during trading on Monday, hitting $17.63. 1,395,550 shares of the company were exchanged, compared to its average volume of 2,295,539. The company has a fifty day moving average price of $20.22 and a 200-day moving average price of $19.70. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.76 and a current ratio of 2.04. Envista has a 12-month low of $15.15 and a 12-month high of $23.00. The firm has a market capitalization of $3.04 billion, a PE ratio of -2.72, a P/E/G ratio of 1.27 and a beta of 1.33.

Envista (NYSE:NVST) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.24 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. As a group, equities research analysts expect that Envista will post 1 EPS for the current year.

Institutional Trading of Envista

Several hedge funds have recently added to or reduced their stakes in the business. Ariel Investments LLC lifted its position in shares of Envista by 6.2% during the 4th quarter. Ariel Investments LLC now owns 12,059,624 shares of the company’s stock valued at $232,630,000 after acquiring an additional 699,625 shares during the last quarter. Nuance Investments LLC grew its holdings in shares of Envista by 4.4% during the third quarter. Nuance Investments LLC now owns 7,346,534 shares of the company’s stock valued at $145,168,000 after buying an additional 308,221 shares in the last quarter. Franklin Resources Inc. raised its position in Envista by 72.6% during the fourth quarter. Franklin Resources Inc. now owns 6,854,506 shares of the company’s stock valued at $132,223,000 after buying an additional 2,882,844 shares during the period. Dimensional Fund Advisors LP grew its stake in Envista by 19.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 6,762,091 shares of the company’s stock valued at $130,440,000 after acquiring an additional 1,089,923 shares in the last quarter. Finally, Gates Capital Management Inc. lifted its position in shares of Envista by 15.1% in the fourth quarter. Gates Capital Management Inc. now owns 4,694,148 shares of the company’s stock worth $90,550,000 after purchasing an additional 615,577 shares in the last quarter.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.